Bempedoic acid: Uses, Dosage, Side Effects, Warnings - Drugs. com Bempedoic acid (brand name Nexletol) is an oral, non-statin, LDL cholesterol-lowering treatment that may be used in adults to: lower the risk of heart attack and heart procedures (for example stent placement or bypass surgery), in those unable to take recommended statin treatment (a cholesterol-lowering medicine), or are not taking a statin, who:
Bempedoic acid (oral route) - Side effects dosage Description Bempedoic acid is used together with diet and other cholesterol-lowering medicines to reduce bad cholesterol (LDL) in patients with primary hyperlipidemia (high blood cholesterol), including heterozygous familial hypercholesterolemia (HeFH) Bempedoic acid is also used to lower the risk of heart attack and heart procedures (eg, stent placement or bypass surgery) in patients who are
Is This New Medication Another Solution For High Cholesterol? Bempedoic acid lowered cholesterol in people who are at high risk of heart disease by 21% Last month, the Journal of the American Medical Association (JAMA) published a study that explored the use of bempedoic acid ― a fairly new medication that was approved by the FDA in 2020 ― as a cholesterol-lowering drug
Bempedoic Acid: Lipid Lowering for Cardiovascular Disease . . . Bempedoic acid was associated with increases in uric acid levels and cholelithiasis, but numerically fewer events of myalgia and new-onset diabetes These findings confirm that bempedoic acid is an effective approach to reduce cardiovascular outcomes in high-risk patients with statin intolerance who require further reduction in LDL-C
Nexletol (bempedoic acid) - Uses, Side Effects, and More Find patient medical information for Nexletol (bempedoic acid) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
Efficacy of Bempedoic Acid, Novel Treatment for Elevated LDL . . . By Anthony Rice Bempedoic acid is a novel non-statin drug produced by Esperion Therapeutics to treat hypercholesterolemia, elevated levels of low-density lipoprotein (LDL) cholesterol in the blood 1 In the double-blind, placebo-controlled, phase 3 2022 CLEAR Outcomes trial conducted by Esperion, bempedoic acid treatment was associated with reductions in major adverse cardiovascular events
Cleveland Clinic-Led Trial Shows that Cholesterol-Lowering . . . After six months of treatment, bempedoic acid, compared with placebo, reduced LDL cholesterol by 23 2% and reduced inflammation measured by C-reactive protein by 22 7% In this primary prevention subgroup, there was also a 30% reduction in major cardiovascular events, a 39% reduction in death from heart disease and a 39% decline in heart attacks
Bempedoic Acid and Cardiovascular Outcomes in Statin . . . In several studies, bempedoic acid reduced the level of LDL cholesterol by 17 to 28%, a finding that, in 2020, prompted its approval by the Food and Drug Administration and the European Medicines
HLS Therapeutics Announces Health Canada Approval of NILEMDO . . . Cardiovascular disease is the second leading cause of death in Canada 1, yet many high-risk patients still cannot achieve guideline-recommended LDL-C targets As a result, more than half a million Canadians may benefit from bempedoic acid 2